Semaglutide is in clinical development for the treatment of overweight and obese adolescents
between the ages of 12 and 17. Obesity is a chronic disease and global public health challenge
and the prevalence of childhood obesity rising in the UK. Obesity increases the risk of developing
a range of health conditions in childhood and later life, including stroke, hypertension and type 2
diabetes.
Semaglutide for treating overweight and obesity in adolescents ages 12 to 17 years old
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Semaglutide is in clinical development for the treatment of overweight and obese adolescents between the ages of 12 and 17.
Interventions:
Semaglutide (Ozempic)
Indications:
Obesity
Therapeutic Areas:
Endocrine Nutritional and Metabolic Disorders
Year:
2022